September 29, 2026
Anaphylaxis can progress to airway compromise or shock within minutes. This standard helps clinicians decide when a patient needs an anaphylaxis response kit on hand at home. It addresses a range of clinical circumstances that may strongly warrant a kit, including first-time doses, medications associated with a known risk of anaphylaxis (e.g., biologics, chemotherapy, and monoclonal antibodies), cross-reactive allergies, and patient-specific risk factors for severe reactions. Limited or delayed access to emergency medical services should also be considered when assessing the need for a kit.
NHIA is requesting that public stakeholders review and provide feedback on the draft practice standard. Your comments on proposed practice standards play a key role in the standards development process. You can comment on all text published within the practice standard section of the following document:
The comment period closes October 30, 2026.
The target audience includes clinicians, regulatory agencies, reimbursement professionals, and industry stakeholders.
Please submit all comments to standards@nhia.org.